Paul Thomas Francis

Paul Thomas Francis

Auto-generated profile, based on publicly available information

Paul Thomas Francis

College of Medicine and Health, University of Exeter, Exeter, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1999 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
PFPaul T Francis
Paul T Francis
APAlan M Palmer
Alan M Palmer
MSMichael Snape
Michael Snape
GWGordon K Wilcock
Gordon K Wilcock
Alzheimer’s disease is one of the most common causes of mental deterioration in elderly people, accounting for around 50%-60% of the overall cases of dementia among persons over 65 years of age. The past two decades have witnessed a considerable research effort directed towards discovering the cause of Alzheimer’s disease with the ultimate hope of developing safe and effective pharmacological treatments. This article examines the existing scientific applicability of the original cholinergic hypothesis of Alzheimer’s disease by describing the biochemical and histopathological changes of neurotransmitter markers that occur in the brains of patients with Alzheimer’s disease both at postmortem and neurosurgical cerebral biopsy and the behavioural consequences of cholinomimetic drugs and cholinergic lesions. Such studies have resulted in the discovery of an association between a decline in learning and memory, and a deficit in excitatory amino acid (EAA) neurotransmission, together with important roles for the cholinergic system in attentional processing and as a modulator of EAA neurotransmission. Accordingly, although there is presently no “cure” for Alzheimer’s disease, a large number of potential therapeutic interventions have emerged that are designed to correct loss of presynaptic cholinergic function. A few of these compounds have confirmed efficacy in delaying the deterioration of symptoms of Alzheimer’s disease, a valuable treatment target considering the progressive nature of the disease. Indeed, three compounds have received European approval for the treatment of the cognitive symptoms of Alzheimer’s disease, first tacrine and more recently, donepezil and rivastigmine, all of which are cholinesterase inhibitors.

1 July 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MTMadhav Thambisetty
Madhav Thambisetty
ASAndrew Simmons
Andrew Simmons
LVLatha Velayudhan
Latha Velayudhan
AHAbdul Hye
Abdul Hye
JCJames Campbell
James Campbell
SLSimon Lovestone
Simon Lovestone
Peripheral compartments including blood and cerebrospinal fluid exhibit signals reflecting neuropathological changes in Alzheimer disease (AD).1,2 In cerebrospinal fluid, these include a decrease in amyloid-β peptide (Aβ) and an increase in total and phosphorylated tau concentrations,3 reflecting amyloid sequestration as plaques and neurofibrillary degeneration, respectively.4,5 Similarly, while numerous articles suggest that plasma concentrations of several metabolites and proteins might represent responses to neuropathological changes in AD,6-11 these findings have not been conclusively replicated.12 A limitation of such studies may be their reliance upon demonstrating changes between affected and unaffected people, a design of study that might identify secondary changes lacking relevance to core disease biology.

5 April 2013 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
YGYonas E. Geda
Yonas E. Geda
LSLon S. Schneider
Lon S. Schneider
LGLaura N. Gitlin
Laura N. Gitlin
DMDavid S. Miller
David S. Miller
GSGwenn S. Smith
Gwenn S. Smith
NINeuropsychiatric Syndromes Professional Interest Area Of Istaart
Neuropsychiatric Syndromes Professional Interest Area Of Istaart

1 January 2004 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
DWDavid G. Wilkinson
David G. Wilkinson
PFPaul T. Francis
Paul T. Francis
ESElias Schwam
Elias Schwam
JPJennifer Payne-Parrish
Jennifer Payne-Parrish

7 November 2005 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
PFPaul T. Francis
Paul T. Francis
Evidence exists for both cholinergic and glutamatergic involvement in the etiology of Alzheimer's disease. Acetylcholine (ACh), a neurotransmitter essential for processing memory and learning, is decreased in both concentration and function in patients with Alzheimer's disease. This deficit and other presynaptic cholinergic deficits, including loss of cholinergic neurons and decreased acetylcholinesterase activity, underscore the cholinergic hypothesis of Alzheimer's disease. The glutamatergic hypothesis links cognitive decline in patients with Alzheimer's to neuronal damage resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors by glutamate. The sustained low-level activation of NMDA receptors, which are pivotal in learning and memory, may result from deficiencies in glutamate reuptake by astroglial cells in the synaptic cleft. This article reviews the roles of ACh and glutamate in Alzheimer's disease, with particular attention given to the overlap between cholinergic and glutamatergic pathways. In addition, the potential synergy between cholinesterase inhibitors and the NMDA receptor antagonist memantine in correcting neurologic abnormalities associated with Alzheimer's disease is addressed.

9 January 2018 in Brain
Verified
Journal Article
Closed access
PDF file
Erika BereczkiErika Bereczki
Erika Bereczki
RBRui M Branca
Rui M Branca
PFPaul T Francis
Paul T Francis
JPJoana B Pereira
Joana B Pereira
JBJean-Ha Baek
Jean-Ha Baek
DADag Aarsland
Dag Aarsland
See Attems and Jellinger (doi: 10.1093/brain/awx360 ) for a scientific commentary on this article. Cognitive changes occurring throughout the pathogenesis of neurodegenerative diseases are directly linked to synaptic loss. We used in-depth proteomics to compare 32 post-mortem human brains in the prefrontal cortex of prospectively followed patients with Alzheimer’s disease, Parkinson’s disease with dementia, dementia with Lewy bodies and older adults without dementia. In total, we identified 10 325 proteins, 851 of which were synaptic proteins. Levels of 25 synaptic proteins were significantly altered in the various dementia groups. Significant loss of SNAP47, GAP43, SYBU (syntabulin), LRFN2, SV2C, SYT2 (synaptotagmin 2), GRIA3 and GRIA4 were further validated on a larger cohort comprised of 92 brain samples using ELISA or western blot. Cognitive impairment before death and rate of cognitive decline significantly correlated with loss of SNAP47, SYBU, LRFN2, SV2C and GRIA3 proteins. Besides differentiating Parkinson’s disease dementia, dementia with Lewy bodies, and Alzheimer’s disease from controls with high sensitivity and specificity, synaptic proteins also reliably discriminated Parkinson’s disease dementia from Alzheimer’s disease patients. Our results suggest that these particular synaptic proteins have an important predictive and discriminative molecular fingerprint in neurodegenerative diseases and could be a potential target for early disease intervention.